SLC27A5 siRNA (Human)

SiRNA to inhibit SLC27A5 expression using RNA interference

Product Specifications

Product Name Alternative

ACSB; ACSVL6; FACVL3; FATP5; Bile acyl-CoA synthetase; BACS; Bile acid-CoA ligase; BA-CoA ligase; BAL; Cholate--CoA ligase; Fatty acid transport protein 5; FATP-5; Fatty-acid-coenzyme A ligase. very long-chain 3; Solute carrier family 27 member 5; Very long-chain acyl-CoA synthetase homolog 2; VLCS-H2; VLCSH2; Very long-chain acyl-CoA synthetase-related protein; VLACS-related; VLACSR

Reactivity

Source

Synthetic

Applications

RNAi

Purity

> 97%

Form

Lyophilized powder

Components

We offers pre-designed sets of 3 different target-specific siRNA oligo duplexes of human SLC27A5 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot.

Storage Conditions

Shipped at 4 °C. Store at -20 °C for one year.

Specificity

SLC27A5 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.

NCBI Gene Symbol

SLC27A5

Quality Control

Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.